Interestingly, CD40-L has been shown to sensitize epithelial ovarian cancer cells to cisplatin treatment, clearly indicating that activation of the CD40 intracellular pathway in cancer cells can be of relevance beyond CD40 effect in establishing the adaptive immune response [31]. This evidence concerns the gene CD40 and ovarian carcinoma.